1. What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

3. Introduction/Overview

4. Key Technologies in EHL Hemophilia Recombinant Factors

5. EHL Agents Extend Half-Life by Improving AUC and Clearance

6. The Importance of Maintaining Trough Levels to Prevent Breakthrough Bleeding

7. Current Unmet Needs in the Treatment of Hemophilia A

8. Phenotypic Variability Among PWH-A

9. Hemophilia A: Replacement Therapy Regimens

10. Long-Acting Factor VIII Replacement Therapies Offer Many Choices Relevant to the PWH-A's Phenotype

11. Benefits of Prophylaxis: Increased the Likelihood of Leading a More Normal Life

12. How Will EHL Concentrates Impact Prophylaxis?

13. rFVIIIFc: A-LONG Study Design

14. Factor VIII Activity vs Time Profile for Long-Acting rFVIIIFc and Standard rFVIII: A-LONG

15. Safety and Efficacy of BAY 94-9027: Study Design of PROTECT VIII

16. PROTECT VIII Summary Results: Bleeding and Dosing

17. AFFINITY Study Design

18. AFFINITY Results: Treatment Regimens Prior to Study Entry and at Study End

19. Safety Results: A-LONG; PROTECT VIII

20. AFFINITY Results: Safety and Tolerability

21. Case Study 1: College-Age Male

22. Case Study 2: Pediatric Patient

23. Summary and Conclusions

24. Abbreviations

25. Abbreviations (cont)